Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 study evaluating daily oral TAK-875 (fasiglifam) 25 and 50 mg in Asia Pacific adults with Type 2 diabetes mellitus was terminated; results were posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• TAK-875 (fasiglifam)

Snippet

Sponsor: Takeda | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: TERMINATED | Results posted: 2015-08-19